Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Sedana Medical AB ( (SE:SEDANA) ).
Sedana Medical AB is set to release its interim report for the third quarter of 2025 on October 24, with a presentation scheduled later that day. The company’s CEO, CFO, and CMO will present the report and address questions, highlighting its ongoing commitment to transparency and stakeholder engagement.
The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK14.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.
More about Sedana Medical AB
Sedana Medical AB is a pioneering medtech and pharmaceutical company specializing in inhaled sedation to enhance patient care during and after sedation. The company offers the Sedaconda ACD medical device and Sedaconda (isoflurane) pharmaceutical for mechanically ventilated patients in intensive care. Sedana Medical operates directly in several European countries and collaborates with external distributors in other regions. Founded in 2005, it is listed on Nasdaq Stockholm and headquartered in Stockholm, Sweden.
Average Trading Volume: 308,250
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.29B
Find detailed analytics on SEDANA stock on TipRanks’ Stock Analysis page.